SynthesisWorld journal of gastroenterology2020
Risk of malignancy in Caroli disease and syndrome: A systematic review.
Synthesis in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 63 citations in OpenAlex.
- Diffuse Caroli's disease with hepatolithiasis: a case report.Journal of surgical case reports · 2026Article
- Recurrent Fever and Biliary Ectasia Leading to the Diagnosis of Caroli Syndrome: A Diagnostic Challenge.Cureus · 2026Article
- Clinical outcomes in Caroli disease and Caroli syndrome: a longitudinal observational cohort study.Scientific reports · 2026Observational
- Ten-year progression of Caroli's disease with portal hypertension despite endoscopic and pharmacological therapy: Implications for liver transplantation-A case report.SAGE open medical case reports · 2026Article
- Novel compound heterozygousFrontiers in medicine · 2026Article
- Clinical outcomes of liver transplantation in Caroli syndrome: a retrospective analysis.Orphanet journal of rare diseases · 2025Article
- Cystic lesions and their mimics involving the intrahepatic bile ducts and peribiliary space: diagnosis, complications, and management.Abdominal radiology (New York) · 2025Review
- A Rare Diagnosis of Caroli Syndrome in a Young Patient.Clinical case reports · 2025Article
- Non-infectious Hepatic Cystic Lesions: A Narrative Review.Current medical imaging · 2025Review
- Caroli disease incidentally discovered in a 23-years old male: A case report.Radiology case reports · 2025Article
- Heritable Chronic Cholestatic Liver Diseases: A Review.Journal of clinical and translational hepatology · 2024Review
- Suspected stenosis in Caroli syndrome: when cholangioscopy can be the game changer.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2024Article
- Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.Cancers · 2024Review
- Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Biliary sepsis complication with congenital hepatic fibrosis: an unexpected outcome.BMC infectious diseases · 2023Article
- Findings of cholangitis in a kidney transplant patient with Caroli disease on FDG PET/CT and MRI.Radiology case reports · 2023Article
- Cystic liver lesions: a pictorial review.Insights into imaging · 2022Review
- Imaging of fibropolycystic liver disease.Abdominal radiology (New York) · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital intrahepatic bile duct dilatation without fibrosis is called Caroli disease (CD), and is called Caroli syndrome (CS) when it has fibrotic and cirrhotic liver morphology. The development of intrahepatic carcinoma is described in both conditions, but the reported incidence varies extensively. Potential risk factors for the malignant transformation were not described. Furthermore, conservative or surgical treatment is performed depending on the extent of cystic malformation, hepatic dysfunction and structural hepatic changes, but little is known about which treatment should be offered to patients with CD or CS and cancer.
aimTo further investigate the malignant transformation in these conditions.
methodsA systematic review of the current literature until January 2019 was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. A search using Medline (PubMed) was performed using a combination of Medical Subject Headings terms "caroli disease", "caroli syndrome", "tumor", "malignant", and "cholangiocarcinoma". Only human studies published in English were used for this systematic review. The following parameters were extracted from each article: year of publication, type of study, number of patients, incidence of malignant tumor, duration of symptoms, age, sex, diagnostics, identification of tumor, surgical therapy, survival and tumor recurrence.
resultsTwelve retrospective studies reporting the courses of 561 patients (53% females) were included in this systematic review. With a mean age of 41.6 years old (range 23 to 56 years old), patients were younger than other populations undergoing liver surgery. Depending on the size of the study population the incidence of cholangiocarcinoma varied from 2.7% to 37.5% with an overall incidence of 6.6%. There were only few detailed reports about preoperative diagnostic work-up, but a multimodal work-up including ultrasound of the liver, computed tomography, magnetic resonance imaging and endoscopic retrograde cholangiopancreatography was used in most studies. Disease duration was variable with up to several years. Most patients had episodes of cholangitis, sepsis, fever or abdominal pain. Tumor detection was an incidental finding of the surgical specimen in most cases because it is currently often impossible to detect tumor manifestation during preoperative diagnostics. Liver resection or liver transplantation was performed depending on the extent of the biliary pathology and additional alterations of the liver structure or function. No postoperative adjuvant chemotherapy was reported, but chemotherapy was administered in selected cases of tumor recurrence. Overall survival rates after one year were low at 36% and a high recurrence rate of up to 75% during the observation period.
conclusionOnly few retrospective studies reported a low tumor incidence. Despite the high rate of mortality and tumor recurrence, definite surgical treatment should be offered as soon as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.